^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    LCAR-M23

    i
    Other names: LCAR-M23, LCAR-M23 CAR-T cell therapy
    Associations

    News

    Trials
    Company:
    Legend Biotech
    Drug class:
    Mesothelin-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    2years
    A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-M23, a CAR-T Cell Therapy Targeting MSLN in Patients With Relapsed and Refractory Epithelial Ovarian Cancer (clinicaltrials.gov)
    P1, N=15, Terminated, Shanghai East Hospital | N=34 --> 15 | Trial completion date: Nov 2024 --> Jun 2022 | Recruiting --> Terminated | Trial primary completion date: Nov 2022 --> Jun 2022; Both the sponsors and collaborator are considering terminating the study.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date • CAR T-Cell Therapy
    |
    MSLN (Mesothelin)
    |
    cyclophosphamide • LCAR-M23